Obesity Management

Lifestyle changes—including eating fruits, vegetables, and whole grains—can help patients, especially those with diabetes or hypertension, improve outcomes.

GLP-1 therapies are being evaluated to treat cardiovascular and kidney diseases in individuals with overweight or obesity.

These therapies are highly beneficial, but can come with a host of gastrointestinal adverse effects that patients may not be prepared to manage alone.

Some patients may have difficulty managing the gastrointestinal adverse effects associated with GLP-1 therapies.

Pfizer joins Eli Lilly and Novo Nordisk in the development of oral GLP-1 receptor agonist candidates.

Previously, data from head-to-head trials of tirzepatide and semaglutide were not available.